Trial record 3 of 32 for:    Open Studies | "Borderline Personality Disorder"

Guanfacine to Treat Borderline Personality Disorder

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2006 by Bronx VA Medical Center.
Recruitment status was  Recruiting
Information provided by:
Bronx VA Medical Center Identifier:
First received: July 31, 2006
Last updated: NA
Last verified: July 2006
History: No changes posted
This study is designed to investigate whether guanfacine (Tenex) is an effective treatment for borderline personality disorder (BPD), an illness often characterized by unstable mood and impulsive aggression. Guanfacine stimulates activity in the front portion of the brain, a region associated with attention and the control of behavior. We believe that guanfacine may improve symptoms of BPD by improving attention and aiding regulation of behavior.

Condition Intervention
Borderline Personality Disorder
Drug: guanfacine (Tenex)

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Guanfacine in the Treatment of Borderline Personality Disorder

Resource links provided by NLM:

Further study details as provided by Bronx VA Medical Center:

Primary Outcome Measures:
  • measures of impulsive aggression
  • measures of affective disturbance
  • measures of social and occupational functioning
  • measures of overall clinical status

Study Start Date: July 2006
Detailed Description:
This is an 8-week treatment study designed to test whether guanfacine is an effective treatment for borderline personality disorder (BPD). Prior to taking the study medication, subjects will have medical and psychiatric evaluations, complete self-report questionnaires, do a functional MRI scan, and complete a set of cognitive tests. While taking the study medication, participants will meet weekly with a study doctor and be administered interviews and questionnaires. At the end of the 8-week trial, participants will be asked to repeat the MRI scan and cognitive tests.

Ages Eligible for Study:   18 Years to 55 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria: This study includes men and women between the ages of 18 and 55 who meet criteria for borderline personality disorder with impulsive aggression.

Exclusion Criteria: Subjects must not currently be taking any psychiatric medications. Subjects must not meet criteria for current substance dependence, current major depression, bipolar disorder, or schizophrenia-spectrum disorders.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00358969

Contact: Emily Hart (212) 241-4459
Contact: David Meyerson (212) 241-9734

United States, New York
Mount Sinai Hospital - Mood & Personality Research Group Recruiting
New York, New York, United States, 10029
Sponsors and Collaborators
Icahn School of Medicine at Mount Sinai
Principal Investigator: Antonia S. New, M.D. Icahn School of Medicine at Mount Sinai
  More Information Identifier: NCT00358969     History of Changes
Other Study ID Numbers: GCO 06-0518 
Study First Received: July 31, 2006
Last Updated: July 31, 2006
Health Authority: United States: Federal Government

Keywords provided by Bronx VA Medical Center:
borderline personality disorder
affective instability

Additional relevant MeSH terms:
Borderline Personality Disorder
Personality Disorders
Mental Disorders
Adrenergic Agents
Adrenergic Agonists
Adrenergic alpha-2 Receptor Agonists
Adrenergic alpha-Agonists
Antihypertensive Agents
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Physiological Effects of Drugs processed this record on May 23, 2016